allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: results from a single center, 1993-2011
نویسندگان
چکیده
background: for adult all patients, the indications and appropriate timing of allogeneic hematopoietic stem cell transplantation (ahsct) continue to be debated. the primary aim of this single-institution study was to compare the results of our adult all patients that had been allografted with those reported in the current literature. subjects and methods: this study included 53 consecutive adults with acute lymphoblastic leukemia (all) who underwent allogeneic hematopoietic stem cell transplantation (ahsct) with myeloablative (92%) and reduced-intensity (8%) conditioning between 1993 and 2011. results: mean patient age was 27 years (sd 8.62) and donor age was 33.7 years (sd 9.47). fourteen patients were in first remission; 21 in ≥2nd remission, 15 in relapse and 3 had primary refractory leukemia. thirty-four, 15 and 4 patients received busulfan plus cyclophosphamide, cyclophosphamide/total body irradiation and fludarabine-based regimens, respectively. for graft-versus-host disease (gvhd) prophylaxis, cyclosporine plus methotrexate were used. forty-six donors were related and 7 were unrelated. thirty patients received granulocyte-colony stimulating factor (g-csf) mobilized peripheral blood and 23 received bone marrow as the stem cell source. twenty-six patients relapsed at a mean duration of 11.3 months (sd 19.1). forty-four patients succumbed to their disease after a mean follow-up of 13.6 months (sd 19.5). the cause of mortality was relapse (n=24; 54.5%) and transplant-related etiologies (n=20; 45.5%). the estimated five year probabilities of overall survival (os) and progression-free survival (pfs) were 37% and 12%, respectively. conclusion : by multivariate analyses, transplantation in first remission was the most important predictor of transplant success.
منابع مشابه
Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1993-2011
Background: For adult ALL patients, the indications and appropriate timing of allogeneic hematopoietic stem cell transplantation (AHSCT) continue to be debated. The primary aim of this single-institution study was to compare the results of our adult ALL patients that had been allografted with those reported in the current literature. Subjects and Methods: This study included 53 consecutive adul...
متن کاملallogeneic stem cell transplantation outcome in acute lymphoblastic leukemia patients
introduction: despite achievement to complete remission (cr) with current treatments and new multiple chemotherapeutic agents in acute lymphoblastic leukemia (all) patients, the majority of them still relapse during long-term follow-up. the use of post- remission therapy will reduce early relapse in these cases, but the best option is still debatable. patients and methods: in this retrospective...
متن کاملRole of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia
Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease, due to the expression of different biological and clinical risk factors, for which allogeneic stem cell transplantation (alloHSCT) is an effective consolidation therapy. The non-relapse mortality of alloHSCT remains significantly higher compared with that of conventional chemotherapy. Therefore, one of the main challenges in t...
متن کاملAllogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.
The role of transplantation in infants with acute lymphoblastic leukemia (ALL) is not defined. We analyzed results of 40 infants diagnosed before age 12 months who received a hematopoietic cell transplant (HCT) between July 1982 and February 2003 in first complete remission (CR1; n = 17), CR2/3 (n = 7), or relapse (n = 16). Patients were conditioned with cyclophosphamide with total body irradia...
متن کاملPreliminary Results of Allogenic Hematopoietic Stem Cell Transplantation of non-M3 Acute Myeloid Leukemia
Background: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT. Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
international journal of hematology-oncology and stem cell researchجلد ۲۰۱۵، شماره ۱۰، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023